Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 14/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.52 |
| ▸ | NPC1 | O15118 | 11/20 | 0.52 |
| ▸ | RAB9A | P51151 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715307 | 1.00 | MEN1 (0.52) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4710359 | 0.84 | MEN1 (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4710358 | 0.84 | MEN1 (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4714501 | 0.83 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4713488 | 0.83 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4713486 | 0.83 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4714503 | 0.83 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1603612 | 0.82 | MEN1 (0.60) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL11631039 | 0.81 | KDM4E (0.57) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL11631034 | 0.81 | KDM4E (0.57) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | claimed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| US-9975860-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-05-22 | — | — | US | disclosed |
| EP-3094625-A1 | ANTI-ANGIOGENIC COMPOUNDS | University College Dublin National University Of Ireland, Dublin (IE) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326122-A1 | Anti-Angiogenic Compounds | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-11-10 | — | — | US | disclosed |
| WO-2015107122-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-07-23 | — | — | WO | disclosed |
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| CN-1203060-C | Pyridine derivatives, compositions and uses thereof | NOVARTIS AG (CH) | 2005-05-25 | — | — | CN | disclosed |
| US-6656957-B1 | Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. | NOVARTIS AG (CH) | 2003-12-02 | — | — | US | disclosed |
| CN-1262676-A | Pyridine derivatives | NOVARTIS AG (CH) | 2000-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326122-A1 | Anti-Angiogenic Compounds | VEGFA, FLT4, FLT1 | MEN1 3923/4885KMT2A 4855/4885NPC1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.